bcl-2、p53表达与乳腺癌预后的关系

目的：探讨ｂｃｌ２ 、ｐ５３ 表达与乳腺癌预后的关系。方法：应用免疫组化ＬＳＡＢ法检测６４ 例乳腺癌及３０ 例乳腺良性病变的表达。分析ｂｃｌ２、ｐ５３ 与乳腺癌组织学分级、腋淋巴结转移、复发和预后的关系。结果：ｂｃｌ２ 与ｐ５３ 表达之间差异有显著性,呈负相关（ Ｐ＜ ０－０５） 。ｂｃｌ２ 和ｐ５３ 表达与组织学分级有关（ Ｐ＜ ０－０５） ,ｂｃｌ２ 表达随分级增加阳性率降低,ｐ５３ 则相反。ｐ５３ 表达与腋淋巴结转移有关（ Ｐ＜ ０－０５） 。ｂｃｌ２ 表达与腋淋巴结转移无关（ Ｐ＞ ０－０５） 。ｐ５３ 表达复发组明显高于无复发组（ Ｐ＜０－０５）;ｂｃｌ２ 表达与有无复发无关（Ｐ＞０－０５）。ｐ５３ 表达阳性率≤５ 年生存组明显高于＞ ５ 年生存组,呈负相关（ Ｐ＜ ０－０５）;ｂｃｌ２ 表达与生存期无关（Ｐ＞ ０－０５） 。结论：ｂｃｌ２ 表达与预后无关,其阳性表达可反映肿瘤属分化较好或属早期阶段。ｐ５３ 可单独作为预后指标;ｐ５３ 表达与预后呈负相关。     

膀胱尿路上皮癌HER2表达及临床病理分析

目的 探讨膀胱尿路上皮癌(bladder urothelial carcinoma, BUC)中HER2的表达情况,并分析其临床意义。方法 收集膀胱非浸润性低级别BUC 27例、非浸润性高级别BUC 5例、浸润性高级别BUC 60例,采用免疫组化MaxVision法法检测各组织样本中HER2蛋白的表达,并分析HER2表达与临床病理特征的关系。通过GEPIA数据库或直接在肿瘤基因组图谱(The Cancer Genome Atlas, TCGA)中分析HER2(ERBB2)表达与BUC的关系。结果 浸润性高级别BUC中HER2 2+/3+表达率(26.67%,16/60)显著高于非浸润性低级别BUC(7.41%,2/27)和非浸润性高级别BUC(0,0/5)(P<0.05)。多灶性浸润性高级别BUC中HER2 2+/3+表达率(75.00%,6/8)显著高于单灶性患者(19.23%,10/52)(P<0.05)。各组织学亚型中HER2 2+/3+表达率差异有统计学意义(P<0.05),其中普通型为30%(6/20)、腺样分化型为57.14%(4/7)、微乳头型为66.6...     

声带早期癌DNA分析及p53、Ki-67和bcl-X的表达

目的　以声带原位癌和早期微小浸润癌为主要研究对象 ,探讨声带从良性到恶性病变各阶段中DNA倍体及基因表达的变化 ,并结合其临床生物学行为 ,深入了解其实质。方法　对 18例声带肿瘤性病变做激光扫描细胞DNA分析并进行随访。对 6 2例声带病变 ,以声带原位癌 (CIS)和早期微小浸润癌 (EMIC)为主 ,与声带浸润性癌、声带息肉分别分为 3组 ,检测p5 3、Ki 6 7和bcl X的基因表达并作各组间对比。 结果　DNA倍体分析表明CIS、EMIC和浸润性癌不同 ,前两者几乎都是二倍体 ,而后者 90 %为异倍体 ;随访结果示CIS、EMIC病人无 1例死于肿瘤 ;还发现DNA二倍体和有DNA凋亡峰的肿瘤患者预后好 ,而肿瘤呈异倍体的患者预后差。免疫表型 :p5 3蛋白在声带肿瘤性病变中表达异常高 ;86 %的CIS、EMIC和 91%的浸润性癌都表达p5 3蛋白 ,阳性指数分别为 2 35和 2 2 6 ,同时此两组的Ki 6 7的阳性平均指数也分别为 2 9%和 2 7% ,与声带息肉差异有显著性 (P <0 0 1)。另一方面 ,bcl X的表达从良性病变到恶性病变呈递减态势 ,以浸润性癌中下降最明显 ,与息肉病变差异有显著性 (P =0 0 0 2 )。结论　声带良性病变、CIS、EMIC及浸润性癌在基因表达和DNA倍体上表现有所不同 ,提示它们各自之间有本质的差别 ,声带原位癌的表现界于良恶     

胃肠道间质瘤中p16、p27、Ki-67表达

目的探讨胃肠道间质瘤中p16、p27和Ki67表达与临床预后的关系。方法根据核分裂象的多少、肿瘤体积的大小及有无浸润等将胃肠道间质瘤划分为良性、交界性和恶性,并运用免疫组化SP方法检测p16、p27和Ki67在胃肠道间质瘤中的表达,并统计分析其良性、交界性、恶性和复发死亡病例中的表达差异。结果p16、p27和Ki67的阳性表达率分别为48%、26%和24%。p16在良、恶性中的表达无明显差异,但在良性和交界性中的表达与复发和转移相关;p27低标记指数和Ki67高标记指数与复发和转移相关。结论p16、p27和Ki67在胃肠道间质瘤中的表达对判断预后有价值。     

p16、p53和Ki-67蛋白在宫颈上皮内瘤变中的表达及意义

目的 探讨p16、p53和Ki-67蛋白在宫颈上皮内瘤变(cervical intraepithelial neoplasia,CIN)中的表达及临床意义.方法 采用免疫组化SP法检测正常子宫颈或炎性病变组织、CIN1～3中p16、p53和Ki-67蛋白的表达.结果 p16、p53和Ki-67蛋白在正常子宫颈或炎性病变中罕见表达,在CIN1～3组织中三者表达均较高,随CIN级别升高p16、p53和Ki-67表达增强,各组间表达差异有统计学意义(P<0.05).同时p16、p53和Ki-67三者阳性表达均可见分层现象,在CIN1中大部分阳性细胞位于子宫颈鳞状上皮的下1/3,在CIN2中多累及上皮下2/3,而CIN3则普遍超过上皮的下2/3或全层弥漫阳性,各组间差异具有统计学意义(P<0.05).结论 p16、p53和Ki-67蛋白表达均与子宫颈上皮内瘤变的病变进展密切相关,联合检测p16和Ki-67的抗原表达可作为CIN分级诊断的辅助方法,具有较好的应用价值.     

bcl-2、ki-67和p53在喉鳞状细胞癌中的表达及临床意义

目的:探讨bcl-2、ki-67和p53在喉鳞状细胞癌中的表达及临床意义。方法:采用SP免疫组织化法检测60例喉鳞状细胞癌患者bcl-2、ki-67和p53的表达,并结合临床病理因素进行分析。结果:喉鳞状细胞癌中bcl-2、P53、Ki-67的阳性表达率分别为60.0%(36/60)、53.3%(32/60)、30.0%(18/60)。喉鳞状细胞癌患者的bcl-2、P53和Ki-67阳性表达与组织学分级及淋巴结转移密切相关,组织学分级越低,伴有淋巴结转移的喉鳞状细胞癌患者的bcl-2、P53和Ki-67阳性表达率明显高于其他组(P0.05),但与年龄、肿瘤大小并无显著相关性(P0.05)。结论:bcl-2、ki-67和p53是评价喉鳞状细胞癌预后的较好指标,三者联合检测有助于判断喉鳞状细胞癌的病理临床特征。     

非霍奇金淋巴瘤中McM7、p53和Ki-67的表达

目的 探讨McM7、p53和Ki-67在非霍奇金淋巴瘤（NHL）中表达的意义及相互关系。方法 应用组织芯片和免疫组化S-P法检测McM7、p53和Ki-67在9例反应性增生淋巴结、175例NHL组织中的表达。结果 NHL各组中McM7标记指数（1abelling index,LI）均高于Ki-67 LI;惰性组中McM7 LI和Ki-67 LI低于侵袭性组和高度侵袭性组,差异有显著性（P＜0．05）。NHL中p53表达的阳性率为23．4％,p53在惰性组、侵袭性组及高度侵袭性组之间的表达差异无显著性（P＞0．05）。Ki-67、p53和McM7三者在NHL中的表达呈平行关系（P＜0．01）。结论 McM7是反映细胞增殖的良好指标,作用优于Ki-67,其表达指数与NHL的组织分型、细胞增殖及恶性程度有关。p53基因突变在大多数NHL的发生、发展中可能并不是一个主要的分子事件。     

p53和bcl-2蛋白过度表达与大肠癌生物学行为的关系

目的：探讨p53蛋白和bcl－2蛋白共同表达与大肠癌生物学行为的关系。方法：应用免疫组织化学染色ABC法检测p53蛋白及bcl－2蛋白在67例大肠癌组织中的表达。结果：全阴性组和p53阴性bcl－2阳性组的PCNA增殖指数低于p53阳性bcl－2阴性组及全阳性组（P＜0．01或P＜0．05）。全阳性、p53阳性bcl－2阴性组及p53阴性bcl－2阳性组均多呈浸润性生长（P＜0．01或P＜0．05）。全阳组浸润深度多至浆膜外（P＜0．01或P＜0．05）。两蛋白全阴性组5年生存率高（P＜0．05）。P53和bcl－2蛋白表达与大肠癌Dukes分期、淋巴结转移和组织学类型均无统计学意义。结论：bcl－2蛋白表达对细胞增殖的相关性不大。主要是p53蛋白的作用。只要有1种蛋白表达时大肠癌即多呈浸润性生长，两种蛋白全部阳性组浸润深度较深，蛋白全部阴性组的预后较好，提示p53和bcl－2蛋白的表达情况可部分地反映大肠癌的生物学行为。     

肺癌中P63与P53、E-cadherin、Ki-67表达的比较

目的　比较 p6 3及 p5 3、E cadherin(E cad)、Ki 6 7在肺癌中的表达 ,以了解在不同组织类型肺癌发生发展过程中 ,p6 3与抑癌基因 (p5 3)突变、上皮分化标志基因 (E cad)失活及细胞增殖标志基因 (Ki 6 7)激活有无相关性。方法　采用免疫组化S P法分别检测 6 1例原发性肺癌中 p6 3、p5 3、E cad和Ki 6 7的表达情况。 结果　p6 3在肺鳞癌中阳性率为 10 0 0 % ,而在其他组织类型肺癌中 p6 3基本不表达 ,差异有显著性 (P <0 0 5 ) ;在不同分化程度的肺鳞癌中 p6 3、p5 3的表达差异有显著性 (P<0 0 5 ) ,E cad、Ki 6 7的表达差异无显著性 (P >0 0 5 ) ;E cad的表达在小细胞肺癌与肺鳞癌和肺腺癌之间差异有显著性 (P <0 0 5 ) ;Ki 6 7的表达在各种组织类型肺癌之间差异有显著性 (P <0 0 5 ) ;在不同分化程度鳞癌中 p6 3与E cad的表达呈负相关(P <0 0 5 )。结论　p6 3可作为鳞状上皮源性肿瘤标记物 ,是判断鳞状细胞癌的增殖和分化有意义的指标 ,并可作为鉴别分化差的鳞癌和腺癌、小细胞癌的指标。     

免疫组化检测Ki-67、 HER-2、 CD44、 CK20在膀胱非浸润性乳头状尿路上皮癌分级中的应用

目的探讨免疫组化检测Ki-67、HER-2、CD44、CK20在鉴别低级别和高级别非浸润性乳头状尿路上皮癌中的有效性。方法收集642例分级明确的乳头状尿路上皮癌及57例分级不确定的乳头状尿路上皮癌,根据有无高级别复发或进展,将分级不确定病例分为高危组及低危组,采用免疫组化EnVision法检测Ki-67、HER-2、CD44、CK20的表达。结果将Ki-67≥30%、HER-2全层表达、CD44表达减弱、CK20全层表达定义为阳性,分级明确病例中,低级别组Ki-67、HER-2、CD44、CK20的阳性率分别为12%、15%、28%、21%,高级别组分别为76%、70%、52%、67%,差异均有显著性(P0.001);分级不确定病例中,低危组Ki-67、HER-2、CD44、CK20的阳性率分别为40%、49%、28%、40%,高危组分别为70%、70%、20%、30%。结论免疫组化检测Ki-67、HER-2、CD44、CK20在低级别和高级别乳头状尿路上皮癌中的表达差异有显著性,可以用于乳头状尿路上皮癌分级的辅助诊断,其中Ki-67和HER-2在鉴别中有重要意义。     

Prognostic significance of Ki-67, p53, and Bcl-2 expression in prostate cancer patients with lymph node metastases: A retrospective immunohistochemical analysis

The prognostic significance of Ki-67, p53, and Bcl-2 expression was evaluated in prostate cancer patients with lymph node metastases. Immunohistochemical staining of archived material obtained from 56 patients was performed by the streptavldin-biotin method. Univariate survival analysis showed that a Ki-67 labeling index (Ki-67 LI) of ≥8.4 in the primary tumor identified a group of patients with a significantly poorer prognosis (P<0.001). Furthermore, a Ki-67 LI of ≥8.7 in the nodal metastatlc tumor was also associated with a poorer prognosis (P<0.01). Multivariate analysis showed that the Ki-67 LI of primary tumors (P<0.01) and lymph node metastases (P<0.01) had independent prognostic value. p53 and Bcl-2 expression had no prognostic value in patients with prostate cancer and lymph node involvement. The Ki-67 LI has more prognostic value than p53 and Bcl-2 expression for patients with prostate cancer that has spread to the lymph nodes.     

大肠肿瘤中p53和bcl-2蛋白的表达

目的：研究Ｐ５３和ｂｃｌ－２在大肠肿瘤发生中的作用。方法：应用免疫组化Ｓ－Ｐ法分别检测大肠正常、腺瘤及腺癌中Ｐ５３和ｂｃｌ－２表达。结果：大肠腺癌Ｐ５３表达率高于腺瘤组;Ｐ５３表达与大肠癌的临床病理因素无关,ｂｃｌ－２在正常粘膜基底部上皮细胞表达,在腺瘤（７７．５％）和腺（５５％）ｂｃｌ－２表达差异显著,高分化腺癌ｂｃｌ－２表达率（７３．７％）高于差分化癌（４１．２％）,在腺瘤和腺癌中ｂｃｌ－２和     

Expression of topoisomerase II alpha, Ki-67 and p53 in early stage laryngeal carcinomas not featuring vocal cord fixation

AIM: To determine whether topoisomerase II alpha (topoIIa) expression is an additional prognostic marker for less advanced stage laryngeal cancers first treated without surgery. Ki-67 and p53 protein levels were also assessed for comparison. EXPERIMENTAL DESIGN: Formalin-fixed, paraffin-embedded tumor material from 63 cases of squamous cell carcinoma (SCC) of the larynx (glottis, stages 0,1,2) was immunohistochemically stained for topoIIa, Ki-67 (MIB-1) and p53 (DO-7) and the results were compared with clinicopathologic findings. RESULTS: There were 7 stage 0 (TisN0M0), 33 stage I (T1N0M0), and 23 stage II (T2N0M0) SCCs with the TNM classification. Significant differences between carcinomas and normal mucosa were found for the topoIIa-LI, Ki-67-LI, and topoIIa-to-Ki-67 ratio. Regarding histologic grade, a significant difference in topoIIa-to-Ki-67 ratio was evident between well or moderately and poorly differentiated lesions. There were 19 cases of recurrence and 44 cases of nonrecurrence, but no significant differences were found for either of the indices or their ratio. No significant variation with p53 positivity was evident with reference to histologic differentiation, T-factor, clinical course, or proliferation. CONCLUSIONS: The results demonstrate that the topoIIa-to-Ki-67 ratio is a more sensitive parameter reflecting proliferation, for histologic grading of less advanced laryngeal SCCs, than topoIIa- or Ki-67-LIs.     

Expression of cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: prognostic significance and comparison with p53 and bcl-2

Uncontrolled cell proliferation is the hallmark of malignant tumours. Thus, the proliferative potential of tumour cells is an important prognostic factor. However, evaluation of the prognostic significance of the expression of proteins involved in regulation of cell proliferation remains controversial. In the present study, expression of Ki-67, PCNA and cyclin D1 was estimated in a group of 89 surgically resected non-small cell lung carcinomas using immunohistochemistry. The results were compared with expression of bcl-2 and p53 and with clinicopathological parameters including patients' survival. Ki-67 and PCNA were found to be moderately and highly expressed in 39% and 44% of the tumours, respectively. There was a strong correlation between Ki67 and PCNA expression. Forty five of 88 tumours (51%) showed overexpression of cyclin D1. Surprisingly, cyclin D1 was mainly localized in the cytoplasm and only a small group of tumours (9/88, 10%) showed nuclear staining as well. Bcl-2 and p53 expression was observed in 69% and 30% of the tumours, respectively. All these markers were found to be independent of clinicopathological parameters, except for Ki-67 and bcl-2 expression, which was associated with squamous cell carcinomas. It is concluded that none of the markers that were studied can be used as an independent prognostic factor, whereas the following combinations of markers may have favourable prognostic value: p53 positivity and low Ki-67 expression, p53 positivity and lack of cyclin D1 expression, bcl-2 positivity and low Ki-67 expression, and lack of cyclin D1 expression and low Ki-67 expression.     

Immunohistochemical analysis of bcl-2 and p53 expression in breast carcinomas: their correlation with Ki-67 growth fraction

We examined 59 breast cancers for p53 and bcl-2 protein expression by immunohistochemistry. The results were correlated with Ki-67 immunostaining. p53-negativity was noted in 40 cases and the remaining 19 tumours were p53-positive. Thirty-six tumours showed strong expression of bcl-2 and in 23 no staining for this protein was observed. We found statistically significant reverse correlation between expression of p53 and bcl-2 in majority of carcinomas: 31 cases were bcl-2 positive and p53-negative, and 14 tumours were bcl-2-negative and p53-positive. Six carcinomas showed no nuclear staining for Ki-67 and in the remaining 53 the percent of cancer cells positive for Ki-67 ranged from 1 to 60 (mean: 14.6). In these 53 cases we found that bcl-2-positive tumours were characterized by lower proliferation than bcl-2-negative tumours, the mean value of Ki-67 immunostaining being 10.7% and 23.0%, respectively. p53-negative tumours showed lower proliferation than p53-positive tumours: mean Ki-67 index was 10.2% and 23.9%, respectively.We conclude that immunohistochemically detected p53 and bcl-2 proteins show a significant inverse relationship in majority of breast carcinomas and their expression correlates with tumour proliferation (Ki-67 immunostaining).     

p53与Ki67在判断困难的子宫平滑肌肿瘤诊断中的价值

目的：探讨免疫组化方法在疑难的子宫平滑肌肿瘤诊断中的价值。方法：对56例判断困难的子宫平滑肌肿瘤进行光镜形态以及p53和Ki67标记的观察。结果：46例平滑肌瘤主要表现单项形态异常，p53阳性标记占8.7%，Ki67阳性细胞数平均65.87。7例平滑肌肉瘤或恶性倾向未定的平滑肌肿瘤主要表现多项形态异常，p53阳性标记占85%,Ki67阳性细胞数平均683.43。结论：p53与Ki67标记可以共同作为有价值的客观指标，为子宫平滑肌肿瘤的良、恶性判断提供辅助诊断依据。